Harnessing the immunological potential of the gut microbiome: a frontier in autoimmune disease managementThe human gut microbiome, a diverse community of microorganisms inhabiting the intestines, plays a central role in shaping immune function and influencing the development and management of autoimmune diseases (ADs). Beyond aiding digestion, it contributes to intestinal and systemic homeostasis by generating energy from dietary intake, producing vital vitamins, secreting hormones, degrading toxins, and synthesizing essential metabolites (Nayak & Orellana 2024). Additionally, the microbiome supports intestinal immunity, strengthens the epithelial barrier, and protects against pathogenic colonization. Through its influence on a wide array of factors and host processes, it provides critical signals that regulate multiple organs, particularly the immune system (Williams et al. 2023). Recent studies highlight complex interactions among gut microbes, immune cells, and inflammatory pathways, positioning the microbiome as both a biomarker and therapeutic target for ADs.
ADs, characterized by abnormal immune responses against self-antigens, represent a rising global health concern. Despite advances in immunosuppressive therapy, long-term disease control remains unimpressive due to potential side effects and disease heterogeneity. Environmental factors such as diet, foreign materials, stress, lifestyle and climate, combined with genetic susceptibility, contribute to AD risk. Although, the precise mechanisms underlying the onset of ADs remain unclear, growing evidence suggests that gene-environment interactions are key to disease initiation (Miller 2023). According to recent studies, dysbiosis, an imbalance in the gut microbiota, has been implicated in autoimmune inflammation (Haneishi et al. 2023, Shaheen et al. 2022). For example, Prevotella copri correlates with rheumatoid arthritis, while reduced short-chain fatty acid producers like Faecalibacterium prausnitzii are linked to inflammatory bowel disease. Similarly, reduced levels of Bifidobacterium and Alistipes are associated with Sjogren’s syndrome (De Luca & Shoenfeld 2019).
The gut microbiota modulates immune balance through several mechanisms (Figure 1). Metabolites such as butyrate-induce regulatory T cells, which are critical for immune tolerance, while microbial signals maintain barrier integrity and prevent the translocation of inflammatory molecules. Microbiota-derived antigens also influence antibody repertoires and autoantibody production (Chi et al. 2021). Conversely, dysbiosis can promote ADs through microbial translocation via a leaky gut, molecular mimicry between microbial peptides and self-antigens, and aberrant innate immune activation. These processes elevate pro-inflammatory cytokines such as type I interferons, interleukin (IL)-12, and IL-23 while reducing anti-inflammatory mediators like IL-10 and transforming growth factor beta (TGF-β) (Zhang et al. 2020, Mousa et al. 2022).
Illustrates the connection between normal microbiota, dysbiosis, and autoimmune diseases, along with possible ways to address these issues. Normal microbiota maintains immune tolerance and barrier integrity, whereas dysbiosis promotes immune dysregulation and autoimmune disease. Suggested interventions (probiotics, prebiotics, fecal microbiota transplantation, and targeted microbial inoculation) aim to restore microbial balance and prevent dysbiosis.
Given its central role, the gut microbiome is emerging as a therapeutic focus in ADs. Probiotics and prebiotics may restore microbial diversity, enhance immunity, and reduce inflammation. Small-molecule modulators targeting microbial metabolism offer additional promise. However, potential risks, including opportunistic infections or excessive immune activation, necessitate cautious use of these treatments. More advanced strategies such as targeted microbial inoculation and fecal microbiota transplantation have demonstrated benefits in conditions like ulcerative colitis and experimental autoimmune encephalomyelitis. Still, the highly individualized nature of the microbiome, shaped by genetics, diet, age, and environment, complicates the development of standardized therapies (Malik et al. 2023).
To conclude, the gut microbiome represents a frontier in immunological research with potential to transform AD management. Future efforts should focus on identifying disease- specific microbial signatures to enable personalized diagnostics and treatments. Integrating omics technologies such as metagenomics and metabolomics will help unravel how the microbiome interacts with the immune system at a systemic level. Ultimately, these advances may lead to strategies that restore microbial ecosystems, rebalance immunity, and improve health outcomes for patients with ADs.
References
-
CHI M, MA K, WANG J, DING Z, LI Y, ZHU S, LIANG X, ZHANG Q, SONG L & LIU C. 2021. The immunomodulatory effect of the gut microbiota in kidney disease. J Immunol Res 2021: 5516035. https://doi.org/10.1155/2021/5516035.
» https://doi.org/10.1155/2021/5516035 -
DE LUCA F & SHOENFELD Y. 2019. The microbiome in autoimmune diseases. Clin Exp Immunol 195(1): 74-85. https://doi.org/10.1111/cei.13158.
» https://doi.org/10.1111/cei.13158 -
HANEISHI Y, FURUYA Y, HASEGAWA M, PICARELLI A, ROSSI M & MIYAMOTO J. 2023. Inflammatory bowel diseases and gut microbiota. Int J Mol Sci 24(4): 3817. https://doi.org/10.3390/ijms24043817.
» https://doi.org/10.3390/ijms24043817 - MALIK JA, ZAFAR MA, LAMBA T, NANDA S, KHAN MA & AGREWALA JN. 2023. The impact of aging-induced gut microbiome dysbiosis on dendritic cells and lung diseases. Gut Microbes 15(2): 2290643. https://doi.org/10.1080/19490976.2023.2290643.
-
MILLER FW. 2023. The increasing prevalence of autoimmunity and autoimmune diseases: An urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr Opin Immunol 80: 102266. https://doi.org/10.1016/j.coi.2022.102266.
» https://doi.org/10.1016/j.coi.2022.102266 -
MOUSA WK, CHEHADEH F & HUSBAND S. 2022. Microbial dysbiosis in the gut drives systemic autoimmune diseases. Front Immunol 13: 906258. https://doi.org/10.3389/fimmu.2022.906258.
» https://doi.org/10.3389/fimmu.2022.906258 -
NAYAK RR & ORELLANA DA. 2024. The impact of the human gut microbiome on the treatment of autoimmune disease. Immunol Rev 325(1): 107-130. https://doi.org/10.1111/imr.13358.
» https://doi.org/10.1111/imr.13358 -
SHAHEEN WA, QURAISHI MN & IQBAL TH. 2022. Gut microbiome and autoimmune disorders. Clin Exp Immunol 209(2): 161-174. https://doi.org/10.1093/cei/uxac057.
» https://doi.org/10.1093/cei/uxac057 -
WILLIAMS KL, ENSLOW R, SURESH S, BEATON C, HODGE M & BROOKS AE. 2023. Using the microbiome as a regenerative medicine strategy for autoimmune diseases. Biomedicines 11(6): 1582. https://doi.org/10.3390/biomedicines11061582.
» https://doi.org/10.3390/biomedicines11061582 -
ZHANG X, CHEN BD, ZHAO LD & LI H. 2020. The gut microbiota: Emerging evidence in autoimmune diseases. Trends Mol Med 26(9): 862-873. https://doi.org/10.1016/j.molmed.2020.04.001.
» https://doi.org/10.1016/j.molmed.2020.04.001
